CONDUCTING INVESTIGATIONAL DRUG STUDIES FOR INDUSTRY

K. G. Kohlstaedt

DOI: https://doi.org/10.1111/j.1749-6632.1970.tb54760.x

IF: 6.499

Annals of the New York Academy of Sciences

Abstract:Any discussion of the methodology for evaluation of a new drug should be prefaced by a presentation of the procedure that must take place in making a decision that the new substance merits clinical trial in man. I shall restrict my remarks to procedures employed in the clinical trial of an entirely new substance, and I shall not attempt to discuss problems related to evaluation of changes in formulation. Let us assume that the chemists and pharmacologists have produced evidence that a new compound possesses some properties that might have therapeutic application in man. At this time, tests in several species of experimental animals will be undertaken for the purpose of determining any potential toxicity. In addition to undergoing acute tests for lethality, the drug will be administered to animals at regular intervals in the maximum dose they can tolerate, and it will be given by the same route to be used in man. During the administration of the drug, laboratory tests of organ function will be performed at regular intervals. These tests will be terminated at varying times depending on the number of doses planned to be administered in the initial clinical trial. Some of the animals will be sacrificed and subjected to thorough postmortem examination, including careful microscopic examination of tissues. The remainder will continue to receive the drug and be kept under close observation. It is important to keep in mind that the goal of this toxicological testing is to give the drug in sufficient amounts to uncover any undesirable actions. The difference between the quantity of the drug required to produce the desired pharmacologic action in animals and the amount that may cause toxic effects is an important criterion in deciding if a drug merits clinical trial. The occurrence of toxic manifestations in animals when the dosage level is many times the anticipated therapeutic dose should not be held as evidence against initiating a clinical study. However, it is essential that the clinician who will be asked to consider undertaking the clinical trial be informed of all evidence of toxicity and of any abnormalities in organ function that may have been observed during the preclinical studies. It is obvious that we must always weigh the potential for harm against the anticipated benefit that might occur as a result of the addition of a new drug to our therapeutic armamentarium. The first review of these data for this purpose will be made by the research staff that participated in their production and by a physician from the company’s medical research staff who will be responsible for the clinical trial programs. This group will present recommendations to research administration for approval. An important consideration affecting a decision that a new drug merits clinical trial is its intended use. If the new substance would enable us to treat a disease in man for which there is no satisfactory therapy, we would certainly be willing to accept greater potential risk in the clinical trial program than if the drug was intended to